Risk factors associated with seropositivity for Toxoplasma gondii in population-based studies among immunocompromised patients (pregnant women, HIV patients and children) in West African countries, Cameroon and Gabon: A meta-analysis

Toxoplasmosis in immunocompromised individuals can be life threatening. The information needed for proper control and management strategies in endemic West African countries is lacking, hence a systematic review and meta-analysis were performed. This study aimed to determine the seroprevalence of anti-Toxoplasma gondii among pregnant women, HIV/AIDs and children in West Africa, Cameroon and Gabon. The epidemiology of the disease published between 1984 and 2019 using PubMed, Web of Science, Ovid MEDLINE, AJOL and Google Scholar databases were identified. Studies that met the inclusion criteria of Toxoplasma gondii infections under the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist were analysed. A total of 58 eligible studies were selected for meta-analysis. These studies considered 18,674 hosts and an overall pooled seroprevalence of anti-T. gondii antibodies were 45.4, 39.0 and 29.5% for pregnant women, HIV/AIDS patients and children, respectively. Pooled seroprevalence was highest in Gabon and lowest in Mali for pregnant women while highest levels of seropositivity for anti-T. gondii antibodies for HIV/AIDS individuals and children were both observed in Ghana. The major risk factors associated with anti-T. gondii seropositivity were gravida status, contact with cats, consumption of raw vegetables and /fruits, age and CD4 counts. More studies are needed to determine seroconversion rate. Improved sensitization among immunocompromised patients on T. gondii and its risk factors will be an efficient method to reducing the prevalence of the disease. One Health interventions involving transdisciplinary, integrative research and capacity building are necessary to address the problem of toxoplasmosis in West Africa

• Population(s)
  • Women
  • Children or Youth (less than 18 years old)
  • General HIV+ population
  • General HIV- population
• Co-infections
  • Other